335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 26214 | MCL; 70 years or 65 years with co-morbidities that contraindicate autograft; ECOG 2 | Marie Maerevoet | Non-Hodgkin lymphoma | BeiGene | BGB-3111-306 | Trial open for recruitment | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | marie.maerevoet@hubruxelles.be | 3 | 3 | |
| 28641 | - Relapsed cHL (disease progression after PR or CR to the most recent therapy) or refractory cHL (failure to achieve PR or CR to most recent therapy) - Prior therapy targeting PD-1 or PD-L1, anti-PD-L2, or anti CTLA-4 agent = exclusion criteria |
Marie Maerevoet | Multiple | Lysarc | BGB-A317-210/TIRHOL | Trial closed for recruitment | A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (BGB-A317-210/TIRHOL) | marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 22715 | Stage IV unresecable ESCC. Measurable or evaluable disease (RECIST v1.1). ECOG Performance Status ? 1. Adequate organ function. Newly obtained or archival tissue sample available. | Amelie Deleporte | Esophagus | BeiGene | BGB-A317-306 | Trial closed for recruitment | A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | amelie.deleporte@hubruxelles.be | 3 | 3 | |
| 22744 | Second line | Joseph Kerger | Uterus | BGOG | BGOG-cx1/ENGOT-cx1 | Trial closed for recruitment | Randomized double-blind phase II study comparing 3-weekly carboplatin (AUC 5 or 6) + paclitaxel 175 mg/m2 with or without concomitant and maintenance Nintedanib in advanced or recurrent cervical carcinoma | joseph.kerger@hubruxelles.be | 2 | 2 | |
| 22751 | chronic GVHD - already been treated with first-line systemic therapy for at least 1 month - refractoriness or contraindication/intolerance to current therapy | Philippe Lewalle | NA | BHS | BHS-TC11-01 | Trial open for recruitment | A Phase II study to assess the safety and the efficacy of extracorporeal photopheresis using the Theraflex ECPTM (Macropharma) for patients with refractory chronic GVHD | philippe.lewalle@hubruxelles.be | 2 | 2 | |
| 29414 | Hematological malignancies confirmed histologically: - AML in morphological CR or not in morphological CR but not rapidly progressing (i.e. no need to give treatments such as hydroxyurea to maintain WBC count < 10 000 x109/mL); - MDS; - CML in CP or AP; |
Philippe Lewalle | Acute leukemia | BHS | BHS-TC14 | Trial open for recruitment | Allogenic hematopoietic cell transplantation from HLA-matched donor after FLU-Mel-PTCy versus Flu-Mel-ATG reduced intensity conditioning : a phase III randomized study from the Belgian Hematology Society (BHS) | philippe.lewalle@hubruxelles.be | 2 | 2 | |
| 29047 | Nuria Kotecki | Multiple | Boehringer Ingelheim | BI 1472-0001 | Trial closed for recruitment | A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Nuria.Kotecki@hubruxelles.be | 1/1b | 1 | ||
| 22719 | Breast implants | Marie Maerevoet | Lymphoma | Lymphoma Academic Research Organization | BIA-ALCL | Trial open for recruitment | Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry | marie.maerevoet@hubruxelles.be | |||
| 28428 | patients that have initiated reimbursed ibrutinib therapy on or after its launch (via the eHealth procedure) or participated in the Medical Need Program for CLL or MCL and switched to reimbursed ibrutinib on or after 1 August 2015 or had started treatment | Dominique Bron | LLC | Janssen-Cilag N.V. | BiRD | Trial closed | A Retrospective and Prospective Observational Study of ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice Belgian ibrutinib Real-world Data (BiRD) | dominique.bron@hubruxelles.be | |||
| 28640 | RET-fusion | Thierry Berghmans | Lung | Blueprint Medicines Corporation | BLU-667-2303 | Trial closed | A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer | 3 | 3 | ||
| 22700 | Rearranged during transfection(RET) gene altered malignancy | Nuria Kotecki | Multiple | Boston pharmaceuticals | BOS172738 | Trial closed | A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC) | Nuria.Kotecki@hubruxelles.be | 1 | 1 | |
| 22645 | - Histologically confirmed MM with measurable disease per IMWG guidelines - Had at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens |
Nathalie Meuleman | Myeloma | Karyopharm | BOSTON | Trial closed | A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) | nathalie.meuleman@hubruxelles.be | 3 | 3 | |
| 28445 | unresectable liver metastases | Alain Hendlisz | Multiple | Highlight Therapeutics S.L. | BOT112-02 | Trial closed | Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer | alain.hendlisz@hubruxelles.be | 2 | 2 | |
| 23047 | patient métastatique endéans les 2ans (A) ou à l'apparition des métas cérébrales (B) | Andrea Gombos | Multiple | Institut Jules Bordet | BrainStorm program | Trial open for recruitment | A Brain metastases research Platform to tackle the challenge of CNS metastases in solid tumors (BrainStorm program ; IJB-BS-ODN-006) | accueil.oncologie@hubruxelles.be |